Table 4.

Effect of atorvastatin on CVD categorised by combined 1 year achievement of LDL-cholesterol and CRP levels

CVD event (N = 2,258)	Events/persons	Event rate (per 100 person-years)	Adjusted HRa (95% CI)
Major cardiovascular event
Placebo	74/1,115	2.33	1
Atorvastatin subgroups
LDL-c <1.8 mmol/l, CRP <19.0 nmol/l	14/400	1.14	0.44 (0.25, 0.78)
LDL-c <1.8 mmol/l, CRP ≥19.0 nmol/l	16/352	1.59	0.69 (0.40, 1.19)
LDL-c ≥1.8 mmol/l, CRP <19.0 nmol/l	5/177	0.98	0.47 (0.19, 1.16)
LDL-c ≥1.8 mmol/l, CRP ≥19.0 nmol/l	7/214	1.24	0.68 (0.31, 1.47)
Any cardiovascular event
Placebo	116/1,115	3.73	1
Atorvastatin subgroups
LDL-c <1.8 mmol/l, CRP <19.0 nmol/l	24/400	1.99	0.55 (0.35, 0.86)
LDL-c <1.8 mmol/l, CRP ≥19.0 nmol/l	28/352	2.84	0.73 (0.48, 1.12)
LDL-c ≥1.8 mmol/l, CRP <19.0 nmol/l	7/177	1.38	0.41 (0.19, 0.89)
LDL-c ≥1.8 mmol/l, CRP ≥19.0 nmol/l	15/214	2.72	0.69 (0.39, 1.23)

^aAdjusted for age, sex, baseline LDL-cholesterol, baseline CRP, race, smoking status, systolic blood pressure, BMI and HbA_1c

LDL-c, LDL-cholesterol